Masson Kristina's most recent trade in Acrivon Therapeutics Inc was a trade of 490 Common Stock done at an average price of $7.0 . Disclosure was reported to the exchange on Aug. 14, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Acrivon Therapeutics Inc | Kristina Masson | Director, EVP - Business Operations | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.02 per share. | 14 Aug 2024 | 490 | 317,246 | - | 7.0 | 3,440 | Common Stock |
| Acrivon Therapeutics Inc | Kristina Masson | Director, EVP - Business Operations | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.36 per share. | 14 May 2024 | 490 | 317,736 | - | 8.4 | 4,096 | Common Stock |
| Acrivon Therapeutics Inc | Masson Kristina | Director, EVP - Business Operations | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.40 per share. | 14 Feb 2024 | 579 | 318,226 | - | 3.4 | 1,969 | Common Stock |
| Acrivon Therapeutics Inc | Kristina Masson | Director, EVP - Business Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Nov 2022 | 934,731 | 1,806,588 | - | 0 | Common Stock | |
| Acrivon Therapeutics Inc | Kristina Masson | Director, EVP - Business Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Nov 2022 | 503,419 | 2,310,007 | - | 0 | Common Stock | |
| Acrivon Therapeutics Inc | Kristina Masson | Director, EVP - Business Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Nov 2022 | 180,269 | 180,269 | - | - | Stock Option (Right to Buy) | |
| Acrivon Therapeutics Inc | Kristina Masson | Director, EVP - Business Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Nov 2022 | 80,120 | 80,120 | - | - | Stock Option (Right to Buy) | |
| Acrivon Therapeutics Inc | Kristina Masson | Director, EVP - Business Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Nov 2022 | 60,090 | 2,370,097 | - | 0 | Common Stock | |
| Acrivon Therapeutics Inc | Kristina Masson | Director, EVP - Business Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Nov 2022 | 26,707 | 320,705 | - | 0 | Common Stock |